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ABSTRACT 
 
Process Validation emphasizes on process design elements and maintaining process control during 
commercialization and communicate that process validation is an ongoing program and align process validation 
activities with product lifecycle. It has always been known that facilities and processes involved in pharmaceutical 
production impact significantly on the quality of the products. The processes include raw material and equipment 
inspections as well as in-process controls. Process controls are mandatory in good manufacturing practice (GMP). 
 
Keywords: Validation, Master plan, Stages, Types 
 
Introduction 
 
 
Pharmaceutical Process Validation is the most 
important and recognized parameters of cGMPs. The 
concept of validation has expanded through the years 
to embrace a wide range of activities from analytical 
methods used for the quality control of drug substances 
and drug products to computerized systems for clinical 
trials, labelling or process control. Validation 
isfounded on, but not prescribed by regulatory 
requirements and is best viewed as an important and 
integral part of cGMP.[1] According to FDA, 
assurance of product quality is derived from careful 
and systemic attention to a number of importance 
factors, including: selection of quality process through 
in-process and end-product testing.[2] The concept of 
validation was first proposed by two Food and Drug 
Administration (FDA) officials, Ted Byers and Bud 
Loftus, in the mid 1970s in order to improve the quality 
of pharmaceuticals.[3] 
Validation essentialisation 
Validation is an integral part of quality assurance; it 
involves the systematic study of systems, facilities and 
processes aimed at determining whether they perform 
their intended functions adequately and consistently as 
specified.  
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Adequate validation is beneficial to the manufacturer in 
many ways 
• It deepens the understanding of processes; 
decreases the risk of preventing problems and 
thus assures the smooth running of the 
process. 
• It decreases the risk of defect costs. 
• It decreases the risk of regulatory 
noncompliance. 
• A fully validated process may require less in-
process controls and end product testing.[4] 
Validation should thus be considered in the following 
situations: 
• Totally new process 
• New equipment 
• Process and equipment which have been 
altered to suit changing priorities 
•  Process where the end-product test is poor 
and an unreliable indicator of product quality. 
When any new manufacturing formula is adopted, 
steps should be taken to demonstrate its suitability for 
routine processing. [5] 
 
Phases in process validation 
 
 Phase 1:This is the Pre-validation Qualification Phase 
which covers all activities relating to product research 
and development, formulation pilot batch studies, 
scale-up studies, transfer of technology to commercial 
scale batches, establishing stability conditions and 
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storage, and handling of in-process and finished dosage 
forms, equipment qualification, installation 
qualification, master product document, operational 
qualification and process capacity.  
Phase 2: This is the Process Validation Phase. It is 
designed to verify that all established limits of the 
critical process parameter are valid and that satisfactory 
products can be produced even under the worst 
conditions.  
Phase 3: This is known as the Validation Maintenance 
Phase, it requires frequent review of all process related 
documents, including validation of audit reports, to 
assure that there have been no changes, deviations, 
failures and modifications to the production process 
Fig 1:
 
Types of process validation [7-9] 
Prospective Validation 
 
• Conducted prior to the distribution of either a 
new product or a product made under a 
modified production process, where
modifications are significant and may affect 
the products characteristics.
•  It is a preplanned scientific approach and 
includes the initial stages of formulation 
development, process development, setting of 
process specifications, developing in
tests sampling plans, designing of batch 
records, defining raw material specifications, 
completion of pilot runs, transfer of 
technology from scale
commercial size batches, listing major process 
is executed and environmental controls.
•  Validation protocol is executed before the 
process is put into commercial use. 
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and that all standard operating procedures (SOPs), 
including change control procedures, have been 
followed. At this stage, the validation team comprising 
of individuals representing all major departments also 
assures that there have been no changes/deviations th
should have resulted in requalification and revalidation. 
A careful design and validation of systems and process 
controls can establish a high degree of confidence that 
all lots or batches produced will meet their intended 
specifications. It is assumed 
manufacturing and control, operations are conducted in 
accordance with the principle of good manufacturing 
practice (GMP) both in general and in specific 
reference to sterile product manufacture
 Shows decision tree for process validation 
 the 
 
-process 
-up batches to 
 
 
Concurrent Validation 
• A process where current production batches 
are used to monitor processing parameters. It 
gives of the present batch being studied, and 
offers limited assurance regarding consistency 
of quality from batch to batch.
•  Concurrent Validation may be the practical 
approach under certain circumstances. 
Examples of these may be when: A previous 
validated process is being transferred to a 
third party contract man
site. The product is a different strength of a 
previously validated product with the same 
ratio of active/inactive ingredients. 
• The number of lots evaluated under the 
Retrospective Validation was not sufficient to 
obtain a high deg
demonstrating that the process is fully under 
control.  
• The numbers of batches produced are limited. 
• Process with low production volume per batch 
and market demand. 
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• Process of manufacturing urgently needed 
drug due to shortage or absence of supply.  
In all above cases concurrent validation is valid, 
provided following conditions are appropriately.  
 
Retrospective Validation 
 
• Conducted for a product already being 
marketed, and is based on extensive data 
accumulated over several lots and over time.  
• Retrospective Validation may be used for 
older products which were not validated by 
the fabricator at the time that they were first 
marketed, and which is now to be validated to 
confirm to the requirements of division 2, Part 
C of the Regulation to be Food and Drugs Act.  
• Retrospective Validation is only acceptable 
for well established detailed processes and 
will be Inappropriate where there have recent 
changes in the formulation of the products, 
operating procedures, equipment and facility 
•  Some of the essential elements for 
Retrospective Validation are: Batches 
manufactured for a defined period, Number of 
lots released per year,Batch 
size/strength/manufacturer/year/period, 
Master manufacturing/packaging documents, 
List of process deviations, corrective actions 
and changes to manufacturing documents, 
Data for stability testing for several batches, 
Trend analysis including those for quality 
related complaints.  
 
Process Re-Validation 
 
• Required when there is a change in any of the 
critical process parameters, formulation, 
primary packaging components, raw material 
fabricator, major equipment or premises.  
• Failure to meet product and process 
specifications in batches would also require 
process re-validation. 
• Re-Validation becomes necessary in certain 
situations: Changes in raw materials (physical 
properties such as density, viscosity, particle 
size distribution, and moisture, etc., that may 
affect the process or product),Changes in the 
source of active raw material 
manufacturer,Changes in packaging material 
(primary container/closure system),Changes in 
the process (e.g., mixing time, drying 
temperatures and batch size),Changes in the 
equipment (e.g. addition of automatic 
detection system),Changes of equipment 
which involve the replacement of equipment 
on a “like for like” basis would not normally 
require a revalidation except that this new 
equipment, Must be qualified, Changes in the 
plant/facility, Variations revealed by trend 
analysis (e.g. process drifts). 
 
Process validation protocol and master plan 
 
Process validation protocols should include the 
following elements: 
• Objectives, scope of coverage of the 
validation study. 
• Validation team membership, their 
qualifications and responsibilities. 
• Type of validation: prospective, 
concurrent,retrospective, re-validation. 
• Number and selection of batches to be on the 
validation study. 
• A list of all equipment to be used; their 
normal and worst case operating parameters. 
• Outcome of IQ, OQ for critical equipment. 
• Requirements for calibration of all measuring 
devices. 
• Critical process parameters and their 
respective tolerances. 
• Process variables and attributes with probable 
risk and prevention shall be captured. 
• Description of the processing steps: copy of 
the master documents for the product. 
• Sampling points, stages of sampling, methods 
of sampling, sampling plans. 
• Statistical tools to be used in the analysis of 
data. 
• Training requirements for the processing 
operators. 
• Validated test methods to be used in inprocess 
testing and for the finished product. 
• Specifications for raw and packaging 
materials and test methods. 
• Forms and charts to be used for documenting 
results Format for presentation of results, 
documenting conclusions and for approval of 
study results.[10,11] 
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Fig 2
The Validation Master Plan is a top layer document 
and should not go into specific detail; but present an 
overall picture of the company facility,
and capability.  It must give a clear and concise 
overview, to a reviewer, of how the company has 
integrated all the applicable cGMP requirements into 
every aspect of its operations. It must define validation 
activities and allot responsibilities for authoring, 
reviewing, approving, and executing validation 
documentation and tasks. It must define the range of 
documentation spreading from the 
URS, DQ, IQ, OQ, P1Q, and P2Q.  It must explain and 
detail the company’s approach to risk based validation 
and the interaction of the VRA, VA
11. Facilities are portrayed with the use of layered 
drawings; where different layers show individual 
systems and equipment lists give equipme
identity details. It is normal to include layered 
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: Shows process Validation Master Plan 
 organisation 
VMP to the VP, 
, and 21 CFR Part 
nt type and 
drawings to enable a clear and easily observed 
presentation of the following systems.
• Facility building overall location and access.
• Facility production/clerical/
rooms or zones.  
• Raw material ingress and finished product 
egress routes. 
•  Personnel ingress and egress routes, along 
with changing areas.
•  Utility Layouts 
•  Electrical layouts 
• Controlled atmospheric areas along with air 
flow directions and pressure regimes. 
•  Dressing codes for these controlled 
[12]. 
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Pharmaceutical equipment process validation 
Installation Qualification 
 
• This ensures that all major processing and 
packaging equipment, and ancillary systems 
are in conformity with installation 
specification, equipment manuals schematics 
and engineering drawing. 
•  It verifies that the equipment has been 
installed in accordance with manufacturers 
recommendation in a proper manner and 
placed in an environment suitable for its 
intended purpose. 
 
Operational Qualification 
 
• This is done to provide a high degree of 
assurance that the equipment functions as 
intended.  
• Operational qualification should be conducted 
in two stages:Component Operational 
Qualification,of which calibration can be 
considered a large part and System 
Operational Qualification to determine if the 
entire system operates as an integrated 
whole[13,14]. 
 
Process Performance Qualification 
 
• This verifies that the system is repeatable and 
is consistently producing a quality product. 
• These exercises assure, through appropriate 
performance lists and related documentation, 
that equipment, ancillary systems and sub-
systems have been commissioned correctly. 
The end results are that all future operations 
will be reliable and within prescribed 
operational limits [15, 16]. 
 
 
Conclusion 
 
Pharmaceutical Process Validation is the most 
important and recognized parameters of cGMP. It is 
necessary, before approval of a new drug, that an 
accurate and reliable assessment for its effectiveness 
and safety for the intended indication and target patient 
population is demonstrated. Generally, pharmaceutical 
validation and process control provide a certain 
assurance of batch uniformity and integrity of the 
product manufactured. 
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